Glycemic control and complication progression could be acceptable in HNF4A-MODY cases treated with long-time insulin, but risks of hypoglycemic events, obesity, and atherosclerosis remain. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.